ACAD - ACADIA Pharmaceuticals Inc.
| Previous Close | 23.32 |
| Open | 23.27 |
| Bid | 23.57 x 800 |
| Ask | 23.60 x 800 |
| Day's Range | 22.45 - 23.61 |
| 52 Week Range | 12.77 - 28.67 |
| Volume | 2,114,906 |
| Avg. Volume | 1,420,975 |
| Market Cap | 3.393B |
| Beta (3Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.•yesterday
Should ACADIA Pharmaceuticals (NASDAQ:ACAD) Be Disappointed With Their -30% Profit?
While it may not be enough for some shareholders, we think it is good to see the ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) share price up 12% in a single quarter. But that doesn't change the fact that the returns over the last...
- Markit•11 days ago
See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $2.50 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Benzinga•23 days ago
The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 27) Baxter International Inc (NYSE: BAX ) Catalyst Pharmaceuticals ...
- Simply Wall St.•last month
Is ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) Liquidity Good Enough?
Mid-caps stocks, like ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a market capitalization of US$3.8b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT
Q4 2018 ACADIA Pharmaceuticals Inc Earnings Call
- Motley Fool•2 months ago
Why Acadia Pharmaceuticals Stock Perked Up in February
The company's comeback story continued to gain momentum last month.
- TheStreet.com•2 months ago
3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks
Fourth-quarter earnings season is winding down. It disclosed encouraging Phase 2 data for Nuplazid to treat major depressive disorder in October and will start two Phase 3 studies for that indication later this year.
Motley Fool•2 months agoAcadia Pharmaceuticals Inc (ACAD) Q4 2018 Earnings Conference Call Transcript
ACAD earnings call for the period ending December 31, 2018.
- Zacks•2 months ago
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.
- Zacks•2 months ago
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
- Zacks•2 months ago
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
- Zacks•2 months ago
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
- Zacks•2 months ago
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.
- Zacks•2 months ago
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
- Zacks•3 months ago
Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.
- Zacks•3 months ago
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
- Zacks•3 months ago
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.
- Zacks•3 months ago
Will ACADIA Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in ACADIA Pharmaceuticals Inc.
- Simply Wall St.•3 months ago
Does ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) CEO Pay Compare Well With Peers?
Steve Davis became the CEO of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...
- Zacks•3 months ago
Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.
- Yahoo Finance Video•2 months ago
Big Pharma faces the Senate in drug price hearings
Yahoo Finance's Adam Shapiro, Julie Hyman, Jessica Smith, and Brian Sozzi discuss the Pharma executives testifying in the Senate drug price hearings.
